Roivant Sciences

Kythera Labs Announces $20 Million Funding to Accelerate Growth of its Wayfinder Data Technology Platform

Retrieved on: 
Tuesday, November 7, 2023
Roivant Sciences, RWD, CSO, CIBC, Health care, CCO, Arbutus Biopharma, Entrepreneurship, Research, RWE, Growth, Conference on Semantics in Healthcare and Life Sciences, Partnership, Kythira, Chief commercial officer, Databricks, Datavant, Pharmaceutical industry, Wayfinder

FRANKLIN, Tenn., Nov. 7, 2023 /PRNewswire/ -- Kythera Labs, a leading healthcare technology and data analytics company for the Healthcare and Life Sciences industries, announces $20 Million in Series A and debt financing from BIP Ventures and CIBC. The company will use the funds to support the continued growth and scale of Wayfinder, its data-transforming technology platform, and accelerate the development and adoption of new and existing offerings. Kythera also plans to leverage financing to expand partnerships with industry leaders such as Datavant and Databricks.

Key Points: 
  • The company will use the funds to support the continued growth and scale of Wayfinder, its data-transforming technology platform, and accelerate the development and adoption of new and existing offerings.
  • Kythera Labs' data technology platform, Wayfinder, provides access to real-world healthcare data spanning over 8 years, including over 320 million lives with 29.3 billion encounters.
  • Wayfinder corrects, enhances, and adds new dimensions to healthcare data, using a dynamically improving common data model that facilitates data integration.
  • Roivant Sciences adopted Kythera Labs' platform and refined analytics to more efficiently and accurately support its pre-commercialization activities.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Retrieved on: 
Sunday, November 5, 2023
Slate, Prior, Proxy, United Nations Special Committee on Palestine, Disclosure, Committee, Roivant Sciences, Skadden, Arps, Slate, Meagher & Flom, Mergers and acquisitions, Complaint, Pomerantz, LLP, Special, Sumitomo Pharma

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Myovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

Retrieved on: 
Monday, October 30, 2023
Webcast, Cryptocurrency, Online shopping, Video game, Roivant Sciences

BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m.

Key Points: 
  • BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m.
  • ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business update.
  • To access the conference call by phone, please register online using this registration link .
  • The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Retrieved on: 
Friday, October 27, 2023
Slate, Prior, Proxy, United Nations Special Committee on Palestine, Disclosure, Committee, Roivant Sciences, Skadden, Arps, Slate, Meagher & Flom, Mergers and acquisitions, Complaint, Pomerantz, LLP, Special, Sumitomo Pharma

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Myovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

Retrieved on: 
Thursday, October 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Bryant University, Manchester Metropolitan University, FDA, Roivant Sciences, RAS, Strategic planning, Kite Pharma, Food, Accounting, Rare, Johns Hopkins University, Johns, PwC, Investigational New Drug, European Medicines Agency, Biologics license application, Global marketing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Senior, Avutometinib, Celgene, Bachelor of Science, LLP, Regulation, Verastem Oncology, Assurance, Marketing, Head, Lead, Quality, Cancer, AbbVie, Patient, Consultant, MS, Regulatory affairs, Pharmaceutical industry, Management, Finance, Chemistry, Drug discovery

"These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.

Key Points: 
  • "These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.
  • This includes filing for accelerated approval for avutometinib and defactinib in LGSOC and preparing for a commercial launch of this potential first FDA-approved medicine for this patient population," stated Dan Paterson, President and Chief Executive Officer of Verastem Oncology.
  • "This strengthened executive team, combined with Verastem’s significant progress in advancing therapies across RAS pathway-driven cancers, is expected to accelerate our work to bring new therapies to patients with high unmet medical need."
  • Dan Calkins, Chief Financial Officer, joined Verastem Oncology in 2018 and has served as Vice President of Finance since September 2022.

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Retrieved on: 
Monday, October 23, 2023
Bispecific monoclonal antibody, Hart–Scott–Rodino Antitrust Improvements Act, ROG, RO, Fibrosis, Maintenance, Inflammation, Wardwell, Ulcerative colitis, Inflammatory bowel disease, Vant, Partnership, Webcast, TL1A, M.D, Patient, Citigroup, Pharmaceutical industry, Fine chemical, Roivant Sciences, Pfizer

The agreement includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a novel TL1A directed antibody.

Key Points: 
  • The agreement includes the development, manufacturing and commercialization rights in the US and Japan for RVT-3101, a novel TL1A directed antibody.
  • RVT-3101 is a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
  • The global, randomized, double-blinded, placebo controlled trial delivered the first long-term, dose finding data in a large number of patients (n=245).
  • Telavant was jointly formed by Roivant and Pfizer in 2022 to develop and commercialize RVT-3101 in the US and Japan.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Retrieved on: 
Thursday, October 19, 2023
Slate, Proxy, United Nations Special Committee on Palestine, Disclosure, Committee, Roivant Sciences, Skadden, Arps, Slate, Meagher & Flom, Mergers and acquisitions, Complaint, Pomerantz, LLP, Special, Sumitomo Pharma

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).

Key Points: 
  • NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Myovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Antiva Biosciences Strengthens Leadership with Key New Appointments

Retrieved on: 
Thursday, October 19, 2023
Human papillomavirus infection, Astex Pharmaceuticals, KAI, Project management, OB, Health, CIN, Therapy, Pharmacovigilance, FACOG, HPV, CMC, Acquisition, BRCA, Roivant Sciences, Division of Program Coordination, Planning, and Strategic Initiatives, Amgen, Clovis Oncology, Cancer, CMO, Chemistry, Apoptosis, Patient, Diagnosis, Management, Pharmaceutical industry, Medical device, Tuba Mirum (Paus), EU

REDWOOD CITY, Calif., Oct. 18, 2023 /PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of high-risk infections and pre-cancerous lesions caused by human papilloma virus (HPV), today announced several key new appointments designed to strengthen the company's leadership as it continues to advance its lead development candidate, ABI-2280. The company has added Elaine Chien, M.D., FACOG, as chief medical officer, Susan Wilson, Ph.D., as vice president of project management and strategic initiatives, and Rajashree Joshi-Hangal, Ph.D., as vice president of technical operations. Collectively, these individuals bring Antiva significant industry experience in areas directly related to the company's ongoing work in developing innovative treatments for diseases caused by HPV infection.

Key Points: 
  • Collectively, these individuals bring Antiva significant industry experience in areas directly related to the company's ongoing work in developing innovative treatments for diseases caused by HPV infection.
  • "With the closing of our Series E financing earlier this year, Antiva entered an important new phase as we work to advance ABI-2280 into key efficacy studies across multiple indications.
  • Antiva is currently working to advance ABI-2280 into key efficacy studies.
  • She has also held positions of increasing managerial responsibilities in both technical and regulatory CMC areas  at Astex Pharmaceuticals.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Retrieved on: 
Wednesday, October 11, 2023
Slate, Pomerantz, LLP, Disclosure, Skadden, Arps, Slate, Meagher & Flom, Prior, Sumitomo Pharma, Roivant Sciences, Proxy, Complaint, Mergers and acquisitions, United Nations Special Committee on Palestine, Committee, Special

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).

Key Points: 
  • NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Myovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, October 10, 2023
College, Flagship Pioneering, Harbor, Therapy, Roivant Sciences, University, Novartis, Cancer, Memorial University of Newfoundland, AstraZeneca, MDNA, MIT, CMO, Harvard Medical School, Publication, College of American Pathologists, Science, Assistant, Scripps Research, Whitehead Institute, Glioblastoma, Translational medicine, Memorial University of Newfoundland Faculty of Medicine, Pharmaceutical industry, Biochemistry, Oncology, Biogen

TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna’s clinical programs.

Key Points: 
  • TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna’s clinical programs.
  • Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals,” said Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna.
  • Previously, he was the CMO at Stingthera, CMO in Residence at Roivant Sciences and Chief of Medical Oncology at Evelo Biosciences, a Flagship Pioneering company.
  • Dr. Gardner holds a bachelor’s degree in Biochemistry and his medical degree from the University of Cambridge.